These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 31337259)

  • 1. Clinicopathological significance and prognostic implication of programmed death-1 ligand 2 expression in colorectal cancer.
    Pyo JS; Son BK; Chung KH; Oh IH
    Int J Biol Markers; 2019 Sep; 34(3):276-283. PubMed ID: 31337259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer.
    Ko YS; Pyo JS
    Int J Biol Markers; 2019 Jun; 34(2):132-138. PubMed ID: 30852949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy.
    Huang KC; Chiang SF; Chen TW; Chen WT; Yang PC; Ke TW; Chao KSC
    Sci Rep; 2020 Dec; 10(1):22330. PubMed ID: 33339860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy.
    Tanaka K; Miyata H; Sugimura K; Kanemura T; Hamada-Uematsu M; Mizote Y; Yamasaki M; Wada H; Nakajima K; Takiguchi S; Mori M; Doki Y; Tahara H
    Cancer Sci; 2016 Jun; 107(6):726-33. PubMed ID: 27015293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression.
    Pyo JS; Ko SH; Ko YS; Kim NY
    Pathol Res Pract; 2020 Feb; 216(2):152764. PubMed ID: 31836325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.
    Takamori S; Takada K; Azuma K; Jogo Y; Kinoshita F; Kozuma Y; Matsubara T; Haratake N; Akamine T; Toyokawa G; Hirai F; Tagawa T; Okamoto I; Nakanishi Y; Kawahara A; Akiba J; Oda Y; Maehara Y
    Anticancer Res; 2018 Oct; 38(10):5903-5907. PubMed ID: 30275217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2.
    Ariafar A; Ghaedi M; Rezaeifard S; Shahriari S; Zeighami S; Ghaderi A; Faghih Z
    Mol Immunol; 2020 Aug; 124():35-41. PubMed ID: 32512320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer.
    Wu Z; Yang L; Shi L; Song H; Shi P; Yang T; Fan R; Jiang T; Song J
    Biomed Res Int; 2019; 2019():8014627. PubMed ID: 31275983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
    Calik I; Calik M; Turken G; Ozercan IH; Dagli AF; Artas G; Sarikaya B
    Medicina (Kaunas); 2019 Oct; 55(11):. PubMed ID: 31683723
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
    Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
    Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
    Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H
    J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of sidedness of colorectal cancer on tumor immunity.
    Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Kashihara H; Yoshimoto T; Shimada M
    PLoS One; 2020; 15(10):e0240408. PubMed ID: 33045001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer.
    Enkhbat T; Nishi M; Takasu C; Yoshikawa K; Jun H; Tokunaga T; Kashihara H; Ishikawa D; Shimada M
    Anticancer Res; 2018 Jun; 38(6):3367-3373. PubMed ID: 29848685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer.
    Zengin M; Zergeroğlu S; Okcu O; Benek S
    Cell Oncol (Dordr); 2021 Apr; 44(2):423-432. PubMed ID: 33469839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
    Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
    Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
    Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J
    Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
    Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
    BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and prognostic value of PD-L1 and PD-L2 in ovarian cancer.
    Xue C; Zhu D; Chen L; Xu Y; Xu B; Zhang D; Jiang J
    Transl Cancer Res; 2019 Feb; 8(1):111-119. PubMed ID: 35116740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.